Insulet Corporation $PODD Stock Holdings Lifted by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in Insulet Corporation (NASDAQ:PODD) by 144.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,356 shares of the medical instruments supplier’s stock after buying an additional 14,996 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Insulet were worth $3,308,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Elevation Wealth Partners LLC grew its stake in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 104 shares in the last quarter. Activest Wealth Management boosted its holdings in Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 149 shares during the period. WPG Advisers LLC boosted its holdings in Insulet by 169.3% in the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 171 shares during the period. Continuum Advisory LLC purchased a new position in Insulet in the 2nd quarter worth approximately $46,000. Finally, Sound Income Strategies LLC grew its position in Insulet by 4,620.0% in the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 231 shares in the last quarter.

Insulet Trading Up 2.6%

NASDAQ:PODD opened at $153.61 on Tuesday. The stock has a market cap of $10.65 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The business’s 50-day simple moving average is $141.02 and its 200 day simple moving average is $179.25.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the firm earned $1.17 EPS. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PODD shares. Oppenheimer lowered shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Truist Financial cut shares of Insulet from a “buy” rating to a “hold” rating and reduced their target price for the stock from $210.00 to $153.00 in a research report on Wednesday, August 5th. UBS Group decreased their target price on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Finally, Barclays raised shares of Insulet to a “hold” rating in a research note on Wednesday, October 7th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $186.68.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.